The global personalized cell therapy market size is accounted at USD 37.29 billion in 2025 and is forecasted to hit around USD 235.65 billion by 2034, representing a CAGR of 22.81% from 2025 to 2034. The North America market size was estimated at USD 14.79 billion in 2024 and is expanding at a CAGR of 22.82% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Personalized Cell Therapy Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Personalized Cell Therapy Market, by Technique
8.1.1. Platelet Transfusions
8.1.1.1. Market Revenue and Forecast
8.1.2. Bone Marrow Transplantation
8.1.2.1. Market Revenue and Forecast
8.1.3. Packed Red Cell Transfusions
8.1.3.1. Market Revenue and Forecast
8.1.4. Organ Transplantation
8.1.4.1. Market Revenue and Forecast
9.1. Personalized Cell Therapy Market, by Therapeutic Area
9.1.1. Cardiovascular Diseases
9.1.1.1. Market Revenue and Forecast
9.1.2. Neurological Disorders
9.1.2.1. Market Revenue and Forecast
9.1.3. Inflammatory Diseases
9.1.3.1. Market Revenue and Forecast
9.1.4. Diabetes
9.1.4.1. Market Revenue and Forecast
9.1.5. Cancer
9.1.5.1. Market Revenue and Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Technique
10.1.2. Market Revenue and Forecast, by Therapeutic Area
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Technique
10.1.3.2. Market Revenue and Forecast, by Therapeutic Area
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Technique
10.1.4.2. Market Revenue and Forecast, by Therapeutic Area
10.2. Europe
10.2.1. Market Revenue and Forecast, by Technique
10.2.2. Market Revenue and Forecast, by Therapeutic Area
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Technique
10.2.3.2. Market Revenue and Forecast, by Therapeutic Area
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Technique
10.2.4.2. Market Revenue and Forecast, by Therapeutic Area
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Technique
10.2.5.2. Market Revenue and Forecast, by Therapeutic Area
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Technique
10.2.6.2. Market Revenue and Forecast, by Therapeutic Area
10.3. APAC
10.3.1. Market Revenue and Forecast, by Technique
10.3.2. Market Revenue and Forecast, by Therapeutic Area
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Technique
10.3.3.2. Market Revenue and Forecast, by Therapeutic Area
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Technique
10.3.4.2. Market Revenue and Forecast, by Therapeutic Area
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Technique
10.3.5.2. Market Revenue and Forecast, by Therapeutic Area
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Technique
10.3.6.2. Market Revenue and Forecast, by Therapeutic Area
10.4. MEA
10.4.1. Market Revenue and Forecast, by Technique
10.4.2. Market Revenue and Forecast, by Therapeutic Area
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Technique
10.4.3.2. Market Revenue and Forecast, by Therapeutic Area
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Technique
10.4.4.2. Market Revenue and Forecast, by Therapeutic Area
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Technique
10.4.5.2. Market Revenue and Forecast, by Therapeutic Area
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Technique
10.4.6.2. Market Revenue and Forecast, by Therapeutic Area
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Technique
10.5.2. Market Revenue and Forecast, by Therapeutic Area
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Technique
10.5.3.2. Market Revenue and Forecast, by Therapeutic Area
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Technique
10.5.4.2. Market Revenue and Forecast, by Therapeutic Area
11.1. AbbVie Inc.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Bausch Health Companies Inc.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Teva Pharmaceutical Industries Ltd.
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Cipla Inc.
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Lupin
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Sun Pharmaceuticals Industries Ltd.
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Hikma Pharmaceuticals PLC
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. AstraZeneca
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. GSK Plc.
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Pfizer Inc.
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample